Skip to main content
Article thumbnail
Location of Repository

Breast cancer in young women and its impact on reproductive function

By M. Hickey, M. Peate, C.M. Saunders and M. Friedlander
Topics: Reviews
Publisher: Oxford University Press
OAI identifier: oai:pubmedcentral.nih.gov:2667113
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (2003). A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer. Climacteric
    2. (2007). A randomised controlled trial of prophylactic levonorgestrel intrauterine system in tamoxifen-treated women. BJOG
    3. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
    4. (2006). A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update
    5. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.
    6. Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials.
    7. (2005). Adjuvant docetaxel for node-positive breast cancer.
    8. Adjuvant endocrine therapy for premenopausal women with early breast cancer.
    9. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
    10. Advances in breast conservation therapy.
    11. (1997). Ambiguous genitalia in infant exposed to tamoxifen in utero. Lancet
    12. (2005). Amenorrhea in premenopausal women on the doxorubicin (A) and cyclophosphamide (C)-. docetaxel (T) arm of NSABP B-30: Preliminary results.
    13. American College of Radiology appropriateness criteria on conservative surgery and radiation: stages I and II breast carcinoma.
    14. (2006). An open-label, fixed-dose study of bupropion effect on sexual function scores in women treated for breast cancer. Ann Oncol
    15. and menopause-related information needs of younger women with a diagnosis of early breast cancer.
    16. Androgen therapy in women: an Endocrine Society Clinical Practice guideline.
    17. (1996). Annual hazard rates of recurrence for breast cancer after primary therapy.
    18. Assessment of ovarian reserve.
    19. (2000). Association between breast cancer and bone mineral density: the Dubbo Osteoporosis Epidemiology Study. Maturitas
    20. Being breastfed in infancy and breast cancer incidence in adult life: results from the two nurses’ health studies.
    21. (2004). Bilateral prophylactic mastectomy reduces breast cancer risk
    22. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy.
    23. (2003). Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Osteoporos Int
    24. (2007). BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res
    25. (2008). Breast cancer and reproduction 339
    26. (2002). Breast cancer in the very young patient: a multidisciplinary case presentation. Oncologist
    27. (2006). Breast cancer in young women: climbing for progress in care and knowledge. Women’s Health
    28. (1994). Breast cancer in young women: effect of chemotherapy on ovarian function, fertility, and birth defects.
    29. (2008). Breast cancer in young women.
    30. (2005). Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case–control study.
    31. (2008). Breast conservation therapy for stage I or stage II breast cancer: a meta-analysis of randomized controlled trials. Ann Oncol
    32. (1997). Breastfeeding and the use of human milk. Pediatrics
    33. Can patient-, treatment- and pathology-related characteristics explain the high local recurrence rate following breast-conserving therapy in young patients?
    34. Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
    35. (2006). Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol
    36. Chemotherapy-related amenorrhea (CRA) in breast cancer survivors: impact of taxanes on ovarian function. Breast Cancer Res Treat 2004;88:S61–S62. American Academy of Pediatrics. Work Group on Breastfeeding.
    37. Commercialized multigene predictors of clinical outcome for breast cancer.
    38. (1994). Comparative study: replens versus local estrogen in menopausal women. Fertil Steril
    39. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer.
    40. Consensus conference on breast conservation,
    41. (1997). Continuous low dose estradiol released from a vaginal ring versus estriol vaginal cream for urogenital atrophy.
    42. (1992). DeMets DL. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer.
    43. Depomedroxyprogesterone acetate for hot flashes.
    44. Development and testing of a decision aid for breast cancer prevention for women with a BRCA1 or BRCA2 mutation.
    45. (2001). Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials [erratum appears in J Clin Oncol
    46. (2003). Do young breast cancer patients have worse outcomes? J Surg Res
    47. (2007). Early discontinuation of tamoxifen: a lesson for oncologists. Cancer
    48. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial.
    49. Effect of breast-conserving therapy versus radical mastectomy on prognosis for young women with breast carcinoma.
    50. Effect of genetic cancer risk assessment on surgical decisions at breast cancer diagnosis. Arch Surg 2003;138:1323–1328; discussion 1329.
    51. (2005). Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy
    52. (1996). Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women.
    53. Effectiveness of preventive interventions in BRCA1/2 gene mutation carriers: a systematic review.
    54. (2004). Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial.
    55. (2004). Effects of pregnancy after treatment for breast carcinoma on survival and risk of recurrence. Cancer
    56. (2005). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet
    57. Effects of young age at presentation on survival in breast cancer.
    58. Efficacy and safety of sildenafil citrate in women with sexual dysfunction associated with female sexual arousal disorder.
    59. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers.
    60. (1999). Epidemiology of contralateral breast cancer. Cancer Epidemiol Biomarkers Prev
    61. (1996). erratum appears in
    62. Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations.
    63. Fertility in female cancer survivors: pathophysiology, preservation and the role of ovarian reserve testing. Hum Reprod Update 2005;11:69–89.
    64. (2004). Fertility intentions following testing for a BRCA1 gene mutation. Cancer Epidemiol Biomarkers Prev
    65. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation.
    66. (2004). Fertility preservation in female patients. Hum Reprod Update
    67. Fertility preservation in young women undergoing breast cancer therapy.
    68. (2000). Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases. Cancer Epidemiol Biomarkers Prev
    69. Further evidence on the safety and success of ovarian stimulation with letrozole and tamoxifen in breast cancer patients undergoing in vitro fertilization to cryopreserve their embryos for fertility preservation.
    70. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial.
    71. (1994). Goldenhar’s syndrome associated with tamoxifen given to the mother during gestation. JAMA
    72. (2008). Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil Steril
    73. HABITS (hormonal replacement therapy after breast cancer—is it safe?), a randomised comparison: trial stopped.
    74. (2001). Hematological malignancies and pregnancy: a final report of 84 children who received chemotherapy in utero. Clin Lymphoma
    75. (1998). Hot flashes in postmenopausal women treated for breast carcinoma: prevalence, severity, correlates, management and relation to quality of life. Cancer
    76. How subsequent pregnancy affects outcome in women with a prior breast cancer. Oncology (Williston) 1991;5:23–30; discussion 30–21.
    77. (2001). How to diagnose the presence of osteoporosis and assess the risk of fracture. Best Pract Res Clin Rheumatol
    78. (2007). How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries. Oncologist
    79. Implementing a survivorship care plan for patients with breast cancer.
    80. (2003). Increased fracture risk among breast cancer survivors results from the women’s health initiative.
    81. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors.
    82. (2006). Influence of patterns of hormone replacement therapy use and mammographic density on breast cancer detection. Cancer Epidemiol Biomarkers Prev
    83. (1997). Information needs and Breast cancer and reproduction 335decisional preferences in women with breast cancer. JAMA
    84. (2000). Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet
    85. (1995). Lactation after conservative breast surgery combined with radiation therapy.
    86. Late local recurrences in a randomised trial comparing conservative treatment with total mastectomy in early breast cancer patients.
    87. (2006). Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy.
    88. Livebirth after cryopreserved ovarian tissue autotransplantation.
    89. (2006). Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev
    90. Long-term morbidity of patients with early breast cancer after sentinel lymph 338 Hickey et al.node biopsy compared to axillary lymph node dissection.
    91. (2006). Measuring the impact of chemotherapy on fertility in women with breast cancer.
    92. Megestrol acetate for the prevention of hot flashes.
    93. (2005). Menopausal hormone therapy after breast cancer: the Stockholm randomized trial.
    94. (2004). Menopausal status dependence of the timing of breast cancer recurrence after surgical removal of the primary tumour. Breast Cancer Res
    95. Menopausal-type symptoms in young breast cancer survivors.
    96. Menopause after breast cancer: a survey on breast cancer survivors.
    97. Monypenny I et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC trial.
    98. Morbidity comparison of sentinel lymph node biopsy versus conventional axillary lymph node dissection for breast cancer patients: results of the sentinella-GIVOM Italian randomised clinical trial.
    99. Muto MG Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction.
    100. Nipple-sparing mastectomy for breast cancer and risk reduction: oncologic or technical problem?
    101. (2006). Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA
    102. Oncology recommendations on fertility preservation in cancer patients.
    103. or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer.
    104. (2007). Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group. J Clin Oncol
    105. Osteoporosis prevention and treatment.
    106. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer.
    107. (2007). Ovarian function and childbearing issues in breast cancer survivors. Gynecol Endocrinol
    108. (1996). Patient satisfaction with decision-making for breast cancer therapy. Ann Surg Oncol
    109. Phase III trial of gabapentin alone or in conjunction with an antidepressant in the management of hot flashes in women who have inadequate control with an antidepressant alone: NCCTG N03C5.
    110. (1997). Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.
    111. (2008). Practical clinical guidelines for assessing and managing menopausal symptoms after breast cancer. Ann Oncol
    112. Pregnancy after breast cancer: population based study.
    113. (1999). Pregnancy after breast carcinoma: outcomes and influence on mortality. Cancer
    114. (1999). Pregnancy after breast carcinoma: the ultimate medical challenge. Cancer
    115. Pregnancy and breast cancer.
    116. (1994). Pregnancy and lactation after breast-conserving therapy for early stage breast cancer. Cancer
    117. (2008). Preimplantation genetic diagnosis for BRCA1 exon 13 duplication mutation using linked polymorphic markers resulting in a live birth. Prenat Diagn
    118. (1995). Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes towards estrogen replacement therapy.
    119. Prognostic effect of estrogen receptor status across age in primary breast cancer.
    120. Prophylactic tamoxifen. Lancet 1993;342:168. Clark RM, Chua T. Breast cancer and pregnancy: the ultimate challenge.
    121. (1994). Psychological effects of being offered choice of surgery for breast cancer. BMJ
    122. (2004). Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) adjuvant breast cancer trial.
    123. Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal function.
    124. Randomized controlled trial to evaluate transdermal testosterone in female cancer survivors with decreased libido; North Central Cancer Treatment Group protocol N02C3.
    125. Randomized trials of breast-conserving therapy versus mastectomy for primary breast cancer: a pooled analysis of updated results.
    126. Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy. Breast Cancer Res Treat 2008;107:167–180. Cella
    127. (2007). Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case–control study. Lancet Oncol
    128. (1994). Risk of endometrial cancer after tamoxifen treatment of breast cancer.
    129. (2007). Risk-reducing salpingo-oophorectomy in patients with germline mutations
    130. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial.
    131. (1994). Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet
    132. (2002). Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women. J Bone Miner Res
    133. (2008). Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study.
    134. (2008). SEER data submission, posted to the SEER web site).
    135. Selecting breast cancer patients with T1-T2 tumors and one to three positive axillary nodes at high postmastectomy locoregional recurrence risk for adjuvant radiotherapy.
    136. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer.
    137. (2006). Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled study. Lancet Oncol
    138. (2006). Sexual problems in younger women after breast cancer surgery.
    139. Sexual well-being among partnered women with breast cancer recurrence.
    140. Sexuality and body image in younger women with breast cancer.
    141. (1997). Should women be advised against pregnancy after breast-cancer treatment? Lancet
    142. (2007). Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol
    143. Survival after adjuvant oophorectomy and tamoxifen in operable breast cancer in premenopausal women.
    144. Survival effects of postmastectomy adjuvant radiation therapy using biologically equivalent doses: a clinical perspective [erratum appears in
    145. (1994). Survival of breast cancer patients after subsequent term pregnancy: ‘healthy mother effect’.
    146. (1990). Survival of young and older breast cancer patients in Geneva from
    147. (2004). Tamoxifen and pregnancy. Breast
    148. (2001). Tamoxifen treatment and gynecologic side effects: a review. Obstet Gynecol
    149. (2008). Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials.
    150. (2007). Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol
    151. (2006). The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy.
    152. The origins of estrogen receptor alphapositive and estrogen receptor alpha-negative breast cancer.
    153. (1994). The prevalence of menopausal symptoms in patients treated for breast cancer.
    154. The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane.
    155. The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection: a follow-up study of 4008 procedures. Ann Surg 2004;240:462–468; discussion 468–471.
    156. (2007). Therapeutic options for the management of hot flashes in breast cancer survivors: an evidence-based review. Clin Ther
    157. time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study.
    158. (2001). Tolerability of hormone therapies for breast cancer: how informative are documented symptom profiles in medical notes for ‘well-tolerated’ treatments? Breast Cancer Res Treat
    159. (2006). Treatment-induced menstrual changes in very 336 Hickey et al.young (,35 years old) breast cancer patients. Breast Cancer Res Treat
    160. Use of the levonorgestrel-releasing intrauterine system in breast cancer patients.
    161. Vaginal oestrogen therapy after breast cancer: is it safe?
    162. (1999). Vasomotor flushes in menopausal women.
    163. (2002). Very young women (,35 years) with operable breast cancer: features of disease at presentation. Ann Oncol
    164. (2004). Web-based survey of fertility issues in young women with breast cancer.
    165. (2004). What a SWAN can teach us about menopause. Contemp Obstet/Gynecol
    166. (2007). What should I do If I’m at High Risk for Breast Cancer?
    167. (1998). Women 35 years of age or younger have higher locoregional relapse rates after undergoing breast conservation therapy.
    168. Young age and outcome for women with early-stage invasive breast carcinoma.
    169. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression.
    170. (2007). Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.